MDSpire - MDSpire Home

MDSpire - MDSpire Home

Region

United States US publications and network International Global sites and content

The premier global destination for healthcare professionals looking for trusted clinical content, breaking news, and a wealth of educational resources.

Conexiant.com
Conexiant Education

Trusted by leading healthcare organizations to deliver measurable engagement, education, and brand growth.

Conexiant Solutions
Conexiant DXP

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

MDSpire.com
DentalSpire.com

Association Partner

Our vision is a world free from digestive diseases. That's why it's our mission to empower clinicians and researchers to improve digestive health.

gastro.org
agau.org.gastro
myaga.gastro.org
foundation.gastro.org
agajournals.org
healthecareers.com

Conexiant.com
Conexiant Education

Conexiant DXP

MDSpire.com
DentalSpire.com

gastro.org
myaga.gastro.org
agajournals.org
agau.org.gastro
foundation.gastro.org

Advertisement

What is MDSpire?

MDSpire is an innovative platform aiming to create a smarter, faster, and more connected medical community.

Learn More

Choose specialties Cardiology Dermatology Endocrinology Family Medicine Gastroenterology Hematology Internal Medicine Neurology ObGyn Oncology Ophthalmology Optometry Pediatrics Rheumatology Pulmonary Psychiatry Pathology Surgery Orthopedic Medicine Radiology Otolaryngology Infectious Disease

Retinal Physician

May 1, 2026

Clinical Trial Update May/June 2026

May 1, 2026
40 min

A comprehensive overview of active clinical trials focused on age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)

...more

Multiple clinical trials focus on AMD, DME, RVO, and uveitis.
New treatments include ABF-101, BS01, and gene therapies.
Probiotic supplements are being studied for DME.
SGLT2 inhibitors show promise in geographic atrophy.
Trials assess safety, tolerability, and efficacy of novel treatments.
Diverse patient populations are participating.
The role of clinical research in advancing ophthalmic care is emphasized.

Gut

May 1, 2026

Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn’s disease

Longyuan Zhou
Jing Nie
Zhiyin Feng
Rongchang Li
Pingxin Zhang
Sinan Lin
Yao Zhang
Florian Rieder
Changhao Chen
Minhu Chen
Ren Mao
May 1, 2026

Objective: To investigate the role of the pentose phosphate pathway (PPP) and circPLCE1 in fibroblast metabolism and intestinal fibrosis in Crohn's disease, hig

...more

Activation of the pentose phosphate pathway (PPP) in fibroblasts is a key feature of intestinal fibrosis in Crohn's disease.
Xylulokinase (XYLB) generates xylulose-5-phosphate (Xu5P), which promotes collagen synthesis in fibrotic fibroblasts.
CircPLCE1 downregulation in fibroblasts leads to increased PPP activation and collagen production during intestinal fibrogenesis.
CircPLCE1 interacts with XYLB, inhibiting its activity and regulating the PPP and fibrogenesis in intestinal fibrosis.
The circPLCE1/XYLB/Xu5P axis presents a novel therapeutic target for treating intestinal fibrosis in Crohn's disease.

Gut

May 1, 2026

Cause of chronic diarrhoea

Tingting Cao
Honggang Wang
May 1, 2026

Objective: To diagnose the underlying cause of chronic diarrhea in a patient with significant weight loss and gastrointestinal symptoms, emphasizing the urgency

...more

A 52-year-old man presented with chronic diarrhea and significant weight loss, leading to a BMI of 14.9 kg/m².
Laboratory tests indicated anemia, low serum protein, and elevated IgM and β2-microglobulin levels.
Histological examination revealed marked villous blunting and dilated lymphatic vessels in the terminal ileum.
The diagnosis was Waldenström’s macroglobulinaemia with intestinal lymphangiectasia, confirmed by immunophenotyping and genetic testing.
Treatment with the RCD regimen resulted in improved symptoms and nutritional status, with significant regression of intestinal lesions.

Gut

May 1, 2026

Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls

Objective: To analyze the clinical and molecular characteristics of CTNNA1 germline variants and their association with hereditary diffuse gastric cancer (HDGC)

...more

CTNNA1 germline variants are linked to hereditary diffuse gastric cancer (HDGC), with truncating variants posing a moderate risk compared to CDH1 variants.
The study identifies the pathophysiological mechanism for CTNNA1-truncating variants, establishing them as key contributors to HDGC.
Clinical criteria for CTNNA1 genetic testing were proposed, enhancing the identification of individuals at risk for HDGC.
CTNNA1-truncating variants lead to increased likelihood of developing gastric cancer compared to wild-type individuals.
This research provides the largest dataset on CTNNA1-associated diseases, aiding in clinical management and variant classification.

Gut

May 1, 2026

FOXM1 inhibition reduces IL-13-induced epithelial remodelling and inflammation in eosinophilic oesophagitis

Masaru Sasaki
Joshua X Wang
Ryugo Teranishi
Takefumi Itami
Yusen Zhou
Kanak V Kennedy
Ann Semeao
Satoshi Ishikawa
Takeo Hara
Emily A McMillan
Mark Mahon
Hailey Golden
Diya Dhakal
Alyssa Baccarella
Heidi Winters
Chizoba N Umeweni
Benjamin J Wilkins
Tatiana A Karakasheva
Kelly A Whelan
Sydney M Shaffer
Melanie A Ruffner
Amanda B Muir
May 1, 2026

Objective: To investigate the role of FOXM1 in epithelial disruption in eosinophilic esophagitis (EoE) and assess its potential as a therapeutic target, which m

...more

Eosinophilic esophagitis (EoE) is characterized by epithelial remodeling and barrier dysfunction due to T-helper type 2 inflammation.
FOXM1 is identified as a key transcriptional regulator that drives epithelial disruption in EoE.
Inhibition of FOXM1 restores epithelial differentiation, reduces proliferation, and improves barrier integrity in EoE.
Targeting FOXM1 presents a novel therapeutic strategy to enhance epithelial homeostasis and mitigate inflammation in EoE.
This dual approach addressing both epithelial and immune dysregulation may improve patient outcomes in EoE.

Gut

May 1, 2026

Toxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-microbiome study

Cheuk Chun Szeto
Jack K C Ng
May 1, 2026

Objective: To clarify the relationships among gut microbiome composition, diet, and the progression of chronic kidney disease (CKD), highlighting the significan

...more

Dysbiosis in chronic kidney disease (CKD) leads to an overgrowth of harmful bacteria and increased production of uraemic toxins.
Alterations in the gut microbiome of CKD patients are linked to the accumulation of uraemic toxins, which contribute to CKD progression.
Faecal microbiota transplantation in CKD mice showed increased serum uraemic toxins and slight kidney fibrosis, indicating microbiome's role in kidney damage.
Rapid kidney function decline in CKD is associated with gut microbiome-derived metabolites, independent of traditional risk factors.
Dietary interventions, like plant-based, low-protein diets, may mitigate the effects of dysbiosis and uraemic toxin accumulation in CKD.

The Pathologist

April 30, 2026

Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting

April 30, 2026

Objective: To share specific experiences and data from the Mayo Clinic on implementing a large panel liquid biopsy assay for comprehensive genomic profiling, in

...more

Large panel liquid biopsy assays provide comprehensive genomic insights from blood draws, overcoming challenges in cost and technical implementation.
Recent advances in workflows and cost reductions are making liquid biopsy comprehensive genomic profiling more accessible to laboratories.
Plasma workflows offer shorter turnaround times compared to FFPE tissue, facilitating quicker genomic insights when tissue is limited.
The Mayo Clinic has successfully implemented a large panel liquid biopsy assay, demonstrating analytical accuracy and reproducibility.
The webinar will cover the performance of TSO 500 ctDNA v2 and its concordance with solid tumor CGP FFPE tissue assays.

The Analytical Scientist

April 23, 2026

New Frontiers in Non-Target Screening: Roundtable Symposium

April 23, 2026

Objective: To explore emerging frontiers in non-target screening across various fields and identify common challenges faced by researchers. Key Findings: Non-ta

...more

The roundtable symposium focuses on emerging frontiers in non-target screening across various fields.
Advances in high-resolution instrumentation and data analytics are reshaping non-target screening.
Researchers encounter challenges in extracting insights from complex data in non-target screening.
Building robust analytical pipelines is essential for effective non-target screening.
Translating discovery-driven workflows into practical tools is crucial for real-world applications.

The Ophthalmologist

April 22, 2026

Sudden Blindness Reveals Pituitary Apoplexy

April 22, 2026
3 min

Pituitary apoplexy, a rare endocrine emergency often triggered by hemorrhage in a pituitary adenoma, presents critical diagnostic challenges due to the severe v

...more

Pituitary apoplexy is a rare but critical emergency.
Sudden headaches and visual disturbances are key symptoms.
MRI and CT imaging are crucial for diagnosis.
Early treatment can significantly improve outcomes.
The mortality rate can be as high as 15.3% if untreated.
Timely neurosurgical intervention is essential.
Persistent visual deficits may occur despite surgery.

The Ophthalmologist

April 22, 2026

Ocular Surface Control: A Modern Approach to Peri-operative Dry Eye Management

April 22, 2026

Objective: To explore modern strategies for managing peri-operative dry eye and the role of Lacrifill® in ocular surface control. Key Findings: Core principles

...more

The webinar focuses on modern strategies for managing peri-operative dry eye.
It emphasizes the importance of understanding dry eye disease principles aligned with TFOS DEWS III.
Participants will learn practical strategies for identifying and managing peri-operative dry eye.
Effective dry eye management is crucial for improving surgical outcomes and patient experience.
Lacrifill® plays a key role in maintaining consistent ocular surface control during the peri-operative period.

April 18, 2026

How Trump is pushing psychedelics reform through the health agencies

Daniel Payne
April 18, 2026

Objective: To enhance access to psychedelic drugs specifically for treating serious mental illnesses in America. Key Findings: Psychedelics show promise for tre

...more

April 18, 2026

Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role

Helen Branswell
Daniel Payne
Chelsea Cirruzzo
April 18, 2026

Objective: To evaluate the nomination of Erica Schwartz as the new CDC director and the implications of her appointment amidst various political pressures, part

...more

Erica Schwartz has been nominated to lead the CDC, bringing scientific credentials and no ties to the anti-vaccine movement.
Concerns remain about Schwartz's ability to navigate political pressures, particularly from health secretary Robert F. Kennedy Jr.
Experts fear Schwartz may face challenges similar to her predecessor, Susan Monarez, if not allowed to operate independently.
The administration's mixed signals on vaccination policy raise doubts about the CDC's autonomy under Schwartz's leadership.
Schwartz's confirmation may be complicated by a political appointee landscape lacking public health experience.

April 18, 2026

The podcast bringing together MAHA and public health for hard conversations

Torie Bosch
April 18, 2026

Objective: To explore the breakdown of trust between public health and the public, particularly focusing on the Make America Healthy Again (MAHA) movement and v

...more

ASCO AI in Oncology

April 17, 2026

FDA Shoots Down Bid for Review Exemption on Company’s Radiology AI Devices, Citing Safety Gaps

Meg Barbor
April 17, 2026
4 min

Objective: To summarize the FDA's rejection of Harrison.ai's petition for exemption from premarket review for radiology AI devices. Key Findings: Rephrase to di

...more

The FDA denied Harrison.ai's request to bypass premarket review for radiology AI devices, emphasizing the need for safety validation.
Harrison.ai sought exemption for various AI tools, including CADx software, arguing that prior 510(k) clearance should allow future bypass.
The FDA criticized the proposal's reliance on manufacturer self-monitoring, highlighting the lack of independent evaluation mechanisms.
Feedback on the proposal was largely negative, with concerns about patient safety and the immaturity of postmarket AI monitoring.
The FDA suggested Predetermined Change Control Plans as a compromise, allowing pre-approval for future AI updates after initial review.

April 17, 2026

Oklahoma strengthens noncovered services protections in new law

Olivia Anderson
April 17, 2026
5 min

On April 14, 2026, Oklahoma Governor Kevin Stitt signed Senate Bill 1942 into law, clarifying that dental insurers cannot set fees for noncovered services, rest

...more

Senate Bill 1942 prohibits dental insurers from setting fees for noncovered services.
The law restores the intent of the 2010 noncovered services legislation.
Advocated by the Oklahoma Dental Association with ADA support.
Aims to protect small dental practices and uphold patient care decisions.
Came after a decade of advocacy and grassroots efforts.
The law takes effect on November 1, 2026.

April 17, 2026

May Ultraprocessed Foods Raise Muscle Fat?

Andrea Surnit
April 17, 2026
3 min

Research indicates a possible link between the consumption of ultraprocessed foods (UPF) and increased thigh muscle fat infiltration in patients at risk for kne

...more

Higher ultraprocessed food intake linked to increased thigh muscle fat.
Study based on 615 patients without osteoarthritis/hip pain.
UPF accounted for 41% of total dietary intake.
Fat infiltration measured via MRI using Goutallier grading.
Associations stronger in those with high abdominal circumference.
Study has cross-sectional design limitations.
Findings highlight the potential health risks of UPF consumption.
Conducted by researchers from Ankara University and UCSF.

April 17, 2026

Radiology Groups Push Back on New Cancer Screening Guidelines

Kerri Miller
April 17, 2026
2 min

Following the release of updated breast cancer screening guidelines by the American College of Physicians (ACP), two prominent radiology organizations, the Amer

...more

ACP recommends biennial screening for ages 50-
ACR and SBI argue this could lead to 10,000 extra deaths.
They advocate for annual screenings starting at
ACP recommendations are deemed outdated by ACR and SBI.
Debate on screening harms and false positives exists.
ACR and SBI emphasize importance of research-backed practices.
Screening has led to a significant decline in death rates since the 1980s.
Guidelines apply to average-risk, asymptomatic patients.

April 17, 2026

ACP Updates Breast Cancer Screening Guidance

Kerri Miller
April 17, 2026
6 min

Updated guidance from the American College of Physicians recommends biennial mammography for average-risk women aged 50-74, while emphasizing shared decision-ma

...more

Biennial mammography recommended for women aged 50-
Shared decision-making essential for ages 40-
DBT may be considered for women with dense breasts.
Routine MRI/ultrasound not recommended for average-risk individuals.
No clear benefit for screening women over 75 with limited life expectancy.
Clinical breast examination shouldn't be the only screening method.
Significant harms include false positives, overdiagnosis, and psychological distress.

Advertisement

Advertisement

Advertisement

About
Privacy Policy

Follow Us